LY83583 (Standaard)

LY83583 (Standard) is the analytical standard of LY83583. This product is intended for research and analytical applications. LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease[1][2][3].

91300-60-6

12352005

Guanylate Cyclase; Reference Standards

GPCR/G Protein; Others

Cancer; Neurological Disease; Cardiovascular Disease

O=C1C=C(NC2=CC=CC=C2)C(C3=C1N=CC=C3)=O

C15H10N2O2

250.26

[1]Lodygin D, et al. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest. 2002 Dec;110 (11) :1717-27. |[2]Kontos HA, et al. Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke. 1993 Mar;24 (3) :427-34.|[3]Prasad RK, et al. LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels. Eur J Pharmacol. 1999 Jan 29;366 (1) :101-9.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W013386R/

Reference Standards